Barinthus Biotherapeutics (BRNS)
Barinthus Biotherapeutics Statistics
Share Statistics
Barinthus Biotherapeutics has 40.23M shares outstanding. The number of shares has increased by 1.51% in one year.
| Shares Outstanding | 40.23M |
| Shares Change (YoY) | 1.51% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 479 |
| FTD / Avg. Volume | 1.64% |
Short Selling Information
The latest short interest is 16.78K, so 0.04% of the outstanding shares have been sold short.
| Short Interest | 16.78K |
| Short % of Shares Out | 0.04% |
| Short % of Float | 0.07% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -0.78 and the forward PE ratio is -0.74. Barinthus Biotherapeutics's PEG ratio is 0.04.
| PE Ratio | -0.78 |
| Forward PE | -0.74 |
| PS Ratio | 3.18 |
| Forward PS | 2.9 |
| PB Ratio | 0.37 |
| P/FCF Ratio | -1.6 |
| PEG Ratio | 0.04 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Barinthus Biotherapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.03, with a Debt / Equity ratio of 0.09.
| Current Ratio | 8.03 |
| Quick Ratio | 8.03 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | -0.2 |
| Debt / FCF | -0.4 |
| Interest Coverage | -1282.45 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $142,561.9 |
| Profits Per Employee | $-581,657.14 |
| Employee Count | 105 |
| Asset Turnover | 0.09 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -153K |
| Effective Tax Rate | 0.25% |
Stock Price Statistics
The stock price has increased by -47.44% in the last 52 weeks. The beta is -0.76, so Barinthus Biotherapeutics's price volatility has been lower than the market average.
| Beta | -0.76 |
| 52-Week Price Change | -47.44% |
| 50-Day Moving Average | 0.91 |
| 200-Day Moving Average | 1.12 |
| Relative Strength Index (RSI) | 70.3 |
| Average Volume (20 Days) | 29,240 |
Income Statement
In the last 12 months, Barinthus Biotherapeutics had revenue of 14.97M and earned -61.07M in profits. Earnings per share was -1.55.
| Revenue | 14.97M |
| Gross Profit | 9.17M |
| Operating Income | -67.97M |
| Net Income | -61.07M |
| EBITDA | -59.38M |
| EBIT | -61.17M |
| Earnings Per Share (EPS) | -1.55 |
Balance Sheet
The company has 110.66M in cash and 12.01M in debt, giving a net cash position of 98.66M.
| Cash & Cash Equivalents | 110.66M |
| Total Debt | 12.01M |
| Net Cash | 98.66M |
| Retained Earnings | -237.66M |
| Total Assets | 160.33M |
| Working Capital | 110.08M |
Cash Flow
In the last 12 months, operating cash flow was -28.94M and capital expenditures -892K, giving a free cash flow of -29.83M.
| Operating Cash Flow | -28.94M |
| Capital Expenditures | -892K |
| Free Cash Flow | -29.83M |
| FCF Per Share | -0.76 |
Margins
Gross margin is 61.28%, with operating and profit margins of -454.07% and -408%.
| Gross Margin | 61.28% |
| Operating Margin | -454.07% |
| Pretax Margin | -409.03% |
| Profit Margin | -408% |
| EBITDA Margin | -396.7% |
| EBIT Margin | -454.07% |
| FCF Margin | -199.29% |
Dividends & Yields
BRNS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for BRNS is $3, which is 165.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $3 |
| Price Target Difference | 165.5% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Scores
| Altman Z-Score | -1.76 |
| Piotroski F-Score | 3 |